FGF1 Signaling Modulates Biliary Injury and Liver Fibrosis in the Mdr2
ATP Binding Cassette Transporter, Subfamily B
/ metabolism
Animals
Cholangitis, Sclerosing
/ drug therapy
Disease Models, Animal
Fibroblast Growth Factor 1
/ genetics
Fibrosis
Humans
Inflammation
Liver Cirrhosis
/ drug therapy
Male
Mice
Mice, Knockout
MicroRNAs
/ genetics
ATP-Binding Cassette Sub-Family B Member 4
Journal
Hepatology communications
ISSN: 2471-254X
Titre abrégé: Hepatol Commun
Pays: United States
ID NLM: 101695860
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
revised:
21
12
2021
received:
04
09
2021
accepted:
26
12
2021
pubmed:
11
3
2022
medline:
29
6
2022
entrez:
10
3
2022
Statut:
ppublish
Résumé
Fibroblast growth factor 1 (FGF1) belongs to a family of growth factors involved in cellular growth and division. MicroRNA 16 (miR-16) is a regulator of gene expression, which is dysregulated during liver injury and insult. However, the role of FGF1 in the progression of biliary proliferation, senescence, fibrosis, inflammation, angiogenesis, and its potential interaction with miR-16, are unknown. In vivo studies were performed in male bile duct-ligated (BDL, 12-week-old) mice, multidrug resistance 2 knockout (Mdr2
Identifiants
pubmed: 35271760
doi: 10.1002/hep4.1909
pmc: PMC9234675
pii: 02009842-202207000-00008
doi:
Substances chimiques
ATP Binding Cassette Transporter, Subfamily B
0
MIRN16 microRNA, human
0
MicroRNAs
0
Fibroblast Growth Factor 1
104781-85-3
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
1574-1588Subventions
Organisme : BLRD VA
ID : I01 BX000574
Pays : United States
Organisme : BLRD VA
ID : IK2 BX005306
Pays : United States
Organisme : BLRD VA
ID : IK6 BX004601
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK119421
Pays : United States
Informations de copyright
© 2022 The Authors. Hepatology Communications published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.
Références
Popov Y, Patsenker E, Fickert P, Trauner M, Schuppan D. Mdr2 (Abcb4) −/− mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro‐ and antifibrogenic genes. J Hepatol 2005;43:1045‐1054.
Lindström L, Jørgensen KK, Boberg KM, Castedal M, Rasmussen A, Rostved AA, et al. Risk factors and prognosis for recurrent primary sclerosing cholangitis after liver transplantation: a Nordic multicentre study. Scand J Gastroenterol 2018;53:297‐304.
Banales JM, Huebert RC, Karlsen T, Strazzabosco M, LaRusso NF, Gores GJ. Cholangiocyte pathobiology. Nat Rev Gastroenterol Hepatol 2019;16:269‐281.
Wu N, Baiocchi L, Zhou T, Kennedy L, Ceci L, Meng F, et al. The functional role of the secretin/secretin receptor signaling during cholestatic liver injury. Hepatology 2020;72:2219‐2227.
Hirschfield GM, Chazouillères O, Drenth JP, Thorburn D, Harrison SA, Landis CS, et al. Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: a multicenter, randomized, double‐blind, placebo‐controlled phase II trial. J Hepatol 2019;70:483‐493.
Sarabipour S, Hristova K. Mechanism of FGF receptor dimerization and activation. Nat Commun 2016;7:10262.
Li X. The FGF metabolic axis. Front Med 2019;13:511‐530.
Li JT, Liao ZX, Ping J, Xu D, Wang H. Molecular mechanism of hepatic stellate cell activation and antifibrotic therapeutic strategies. J Gastroenterol 2008;43:419‐428.
Schumacher JD, Kong BO, Wu J, Rizzolo D, Armstrong LE, Chow MD, et al. Direct and indirect effects of fibroblast growth factor (FGF) 15 and FGF19 on liver fibrosis development. Hepatology 2020;71:670‐685.
Aqeilan RI, Calin GA, Croce CM. miR‐15a and miR‐16‐1 in cancer: discovery, function and future perspectives. Cell Death Differ 2010;17:215‐220.
Link A, Goel A. MicroRNA in gastrointestinal cancer: a step closer to reality. Adv Clin Chem 2013;62:221‐268.
Kim KM, Han CY, Kim JY, Cho SS, Kim YS, Koo JH, et al. Gα(12) overexpression induced by miR‐16 dysregulation contributes to liver fibrosis by promoting autophagy in hepatic stellate cells. J Hepatol 2018;68:493‐504.
Schelch K, Kirschner MB, Williams M, Cheng YY, Zandwijk N, Grusch M, et al. A link between the fibroblast growth factor axis and the miR‐16 family reveals potential new treatment combinations in mesothelioma. Mol Oncol 2018;12:58‐73.
He Q, Ren X, Chen J, Li Y, Tang X, Wen X, et al. miR‐16 targets fibroblast growth factor 2 to inhibit NPC cell proliferation and invasion via PI3K/AKT and MAPK signaling pathways. Oncotarget 2016;7:3047‐3058.
Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discovery 2010;9:767‐774.
Gavine PR, Mooney L, Kilgour E, Thomas AP, Al‐Kadhimi K, Beck S, et al. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Can Res 2012;72:2045.
Alpini G, Lenzi R, Sarkozi L, Tavoloni N. Biliary physiology in rats with bile ductular cell hyperplasia. Evidence for a secretory function of proliferated bile ductules. J Clin Invest 1988;81:569‐578.
Schoch A, Thorey IS, Engert J, Winter G, Emrich T. Comparison of the lateral tail vein and the retro‐orbital venous sinus routes of antibody administration in pharmacokinetic studies. Lab Animal 2014;43:95‐99.
Yao TJ, Zhu JH, Peng DF, Cui Z, Zhang C, Lu PH. AZD‐4547 exerts potent cytostatic and cytotoxic activities against fibroblast growth factor receptor (FGFR)‐expressing colorectal cancer cells. Tumour Biol 2015;36:5641‐5648.
Zhou T, Kyritsi K, Wu N, Francis H, Yang Z, Chen L, et al. Knockdown of vimentin reduces mesenchymal phenotype of cholangiocytes in the Mdr2 −/− mouse model of primary sclerosing cholangitis (PSC). EBioMedicine 2019;48:130‐142.
Kennedy L, Meadows V, Kyritsi K, Pham L, Kundu D, Kulkarni R, et al. Alemiroation of large bile duct damage by histamine‐2 receptor vivo‐morpholino treatment. Am J Pathol 2020;190:1018‐1029.
Glaser S, Lam IP, Franchitto A, Gaudio E, Onori P, Chow BK, et al. Knockout of secretin receptor reduces large cholangiocyte hyperplasia in mice with extrahepatic cholestasis induced by bile duct ligation. Hepatology 2010;52:204‐214.
Nallagangula KS, Nagaraj SK, Venkataswamy L, Chandrappa M. Liver fibrosis: a compilation on the biomarkers status and their significance during disease progression. Future Sci OA 2017;4:FSO250.
Guo CJ, Pan Q, Li DG, Sun H, Liu BW. miR‐15b and miR‐16 are implicated in activation of the rat hepatic stellate cell: an essential role for apoptosis. J Hepatol 2009;50:766‐778.
Kinoshita M, Uchida T, Sato A, Nakashima M, Nakashima H, Shono S, et al. Characterization of two F4/80‐positive Kupffer cell subsets by their function and phenotype in mice. J Hepatol 2010;53:903‐910.
Koyama Y, Brenner DA. Liver inflammation and fibrosis. J Clin Investig 2017;127:55‐64.
Huda N, Liu G, Hong H, Yan S, Khambu B, Yin X‐M. Hepatic senescence, the good and the bad. World J Gastroenterol 2019;25:5069‐5081.
Qu Y, Liu H, Lv X, Liu Y, Wang X, Zhang M, et al. MicroRNA‐16‐5p overexpression suppresses proliferation and invastion as well as triggers apoptosis by targeting VEGFA expression in breast carcinoma. Oncotarget 2017;8:72400‐72410.
Ehrlich L, O'Brien A, Hall C, White T, Chen L, Wu N, et al. alpha7‐nAChR knockout mice decreases biliary hyperplasia and liver fibrosis in cholestatic bile duct‐ligated mice. Gene Expr 2018;18:197‐207.
Wan Y, Meng F, Wu N, Zhou T, Venter J, Francis H, et al. Substance P increases liver fibrosis by differential changes in senescence of cholangiocytes and hepatic stellate cells. Hepatology 2017;66:528‐541.
Jung D, York JP, Wang LI, Yang C, Zhang A, Francis HL, et al. FXR‐induced secretion of FGF15/19 inhibits CYP27 expression in cholangiocytes through p38 kinase pathway. Pflugers Arch 2014;466:1011‐1019.
Rizvi S, Yamada D, Hirsova P, Bronk SF, Werneburg NW, Krishnan A, et al. A hippo and fibroblast growth factor receptor autocrine pathway in cholangiocarcinoma. J Biol Chem 2016;291:8031‐8047.
Wunsch E, Milkiewicz M, Wasik U, Trottier J, Kempińska‐Podhorodecka A, Elias E, et al. Expression of hepatic fibroblast growth factor 19 is enhanced in primary biliary cirrhosis and correlates with severity of the disease. Sci Rep 2015;5:13462.
Li Z, Lin B, Lin G, Wu Y, Jie Y, Li X, et al. Circulating FGF19 closely correlates with bile acid synthesis and cholestasis in patients with primary biliary cirrhosis. PLoS One 2017;12:e0178580.
Ye D, Li H, Wang Y, Jia W, Zhou J, Fan J, et al. Circulating fibroblast growth factor 21 is a sensitive biomarker for severe ischemia/reperfusion injury in patients with liver transplantation. Sci Rep 2016;6:19776.
Nobuyuki I, Yoshiaki N, Morichika K. Roles of FGFs as paracrine or endocrine signals in liver development, health, and disease. Front Cell Dev Biol 2016;13:30.
Xu Z, Wu Y, Wang F, Li X, Wang P, Li Y, et al. Fibroblast growth factor 1 ameliorates diabetes‐induced liver injury by reducing cellular stress and restoring autophagy. Front Pharmacol 2020;11:52.
Lin H, Zhou C, Hou Y, Li QI, Qiao G, Wang Y, et al. Paracrine fibroblast growth factor 1 functions as potent therapeutic agent for intrahepatic cholestasis by downregulating synthesis of bile acid. Front Pharmacol 2019;10:1515.
Bao L, Yin J, Gao W, Wang Q, Yao W, Gao X. A long‐acting FGF21 alleviates hepatic steatosis and inflammation in a mouse model of non‐alcoholic steatohepatitis partly through an FGF21‐adiponectin‐IL17A pathway. Br J Pharmacol 2018;175:3379‐3393.
Nicholes K, Guillet S, Tomlinson E, Hillan K, Wright B, Frantz GD, et al. A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol 2002;160:2295‐2307.
Yu C, Wang F, Jin C, Huang X, Miller DL, Basilico C, et al. Role of fibroblast growth factor type 1 and 2 in carbon tetrachloride‐induced hepatic injury and fibrogenesis. Am J Pathol 2003;163:1653‐1662.
Nakamura I, Zakharia K, Banini BA, Mikhail DS, Kim TH, Yang JD, et al. Brivanib attenuates hepatic fibrosis in vivo and stellate cell activation in vitro by inhibition of FGF, VEGF and PDGF signaling. PLoS One 2014;9:e92273.
Baiocchi L, Sato K, Ekser B, Kennedy L, Francis H, Ceci L, et al. Cholangiocarcinoma: bridging the translational gap from preclinical to clinical development and implications for future therapy. Expert Opin Investig Drugs 2021;30:365‐375.
Kyritsi K, Francis H, Zhou T, Ceci L, Wu N, Yang Z, et al. Downregulation of p16 decreases biliary damage and liver fibrosis in the Mdr2(/) mouse model of primary sclerosing cholangitis. Gene Expr 2020;20:89‐103.
Wang C, Li Y, Li H, Zhang Y, Ying Z, Wang X, et al. Disruption of FGF signaling ameliorates inflammatory response in hepatic stellate cells. Front Cell Dev Biol 2020;8:601.
An F, Gong B, Wang H, Yu D, Zhao G, Lin L, et al. miR‐15b and miR‐16 regulate TNF mediated hepatocyte apoptosis via BCL2 in acute liver failure. Apoptosis 2012;17:702‐716.
Wu G, Yu F, Xiao Z, Xu K, Xu J, Tang W, et al. Hepatitus B virus X protein downregulates expression of the miR‐16 family in malignant hepatocytes in vitro. Br J Cancer 2011;105:146‐153.
Li L, Masica D, Ishida M, Tomuleasa C, Umegaki S, Kalloo AN, et al. Human bile contains microRNA‐laden extracellular vesicles that can be used for cholangiocarcinoma diagnosis. Hepatology 2014;60:896‐907.
Dewidar B, Meyer C, Dooley S, Meindl‐Beinker N. TGF‐β in hepatic stellate cell activation and liver fibrogenesis‐updated 2019. Cells 2019;8:1419.